F11 mutation screen

Analysis of the F11gene by PCR amplification and sequencing of the coding region and splice junctions is the gold standard approach. Screening for a whole gene deletion is available in cases where no no heterozygosity is detected
Clinical details: 
Factor XI deficiency can not definitively be regarded as either autosomal recessive or dominant. Although homozygotes or compound heterozygotes will have lower plasma factor XI levels than heterozygotes, this does not correlate well with bleeding tendency, unlike haemophilia A or B. Some severely affected individuals (FXI <1 U/dL) remain asymptomatic, whilst some heterozygotes may show a bleeding tendency. Dominant-Negative mutations have also been reported in F11.
Bleeding symptoms, when present, tend to be in the milder range, with no spontaneous joint bleeds etc.
The prevalence of factor XI deficiency is generally quoted as 1:1,000,000 but may be as high as 1:10,000 as it is significantly under-reported due to the absent/mild bleeding diathesis. It is very much more common in the Askhenazi Jewish population at 1:450 and an allele frequency of ~8-13.4%, due mainly to two common founder mutations - p.Glu135* (Type II) and p.Phe301Leu (Type III). Founder mutations have also been identified in the Basque population (p.Cys58Arg), southern France (p.Gln106*) and the north-west of England (p.Cys146*).
Reference range: 


Synonyms or keywords: 
Factor XI deficiency F11 PTA deficiency Rosenthal syndrome Askhenazi Jewish
Sample type and Volume required: 
1 x Edta
Call in advance: 
Turnaround time: 
6 weeks
Storage and transport: 
transport at ambient temperature
Molecular Haemostasis Laboratory at St Thomas'
020 7188 2798
Haemostasis and Thrombosis
North Wing - 4th floor
St Thomas' Hospital
Westminster Bridge Road
London SE1 7EH

Laboratory opening times
Monday - Friday 09.00 - 17.00
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 14/03/2017